
Novo Nordisk’s (NYSE:NVO) nearly 11% pre-market drop on Monday and subsequent 9% dip at market open, in the aftermath of disappointing topline results from its evoke/evoke+ Alzheimer’s trials, is more than a pipeline setback. It’s a stress test for healthcare ETFs that have quietly become GLP-1 momentum vehicles. With two years of outperformance powered by Novo’s Ozempic and Wegovy, and Eli Lilly‘s (NYSE:LLY) Mounjaro and Zepbound, many ETFs now live and die by the swings of just two companies: Novo and Eli Lilly.